CLINICAL TRIALS PROFILE FOR TEPEZZA

All Clinical Trials for TEPEZZA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04583735 ↗	A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease	Recruiting	Horizon Therapeutics USA, Inc.	Phase 4	2021-09-02	The overall objective is to investigate the efficacy, safety and tolerability of TEPEZZA® in participants with chronic (inactive) TED (thyroid eye disease). Approximately 57 participants will be enrolled. There will be a treatment period (through Week 24) and a follow up period (where TEPEZZA will not be infused).
NCT05002998 ↗	TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study	Not yet recruiting	Horizon Therapeutics USA, Inc.	Phase 4	2021-08-01	This is a double-masked, randomized, parallel-assignment, multicenter trial examining the safety and tolerability of teprotumumab in the treatment of Thyroid Eye Disease (TED) in adult participants. This international, Phase 3b/4 trial is being conducted to fulfill an FDA post-marketing requirement for a descriptive trial to evaluate the safety, efficacy and need for re-treatment of 3 different teprotumumab treatment durations for TED. In addition, serum samples from participants with a Baseline Clinical Activity Score (CAS) ≥3 will be evaluated for biomarkers of disease.
NCT06389578 ↗	A Study of TEPEZZA® Treatment in Participants With Thyroid Eye Disease	COMPLETED	Amgen	PHASE1	2022-07-14	The main goal of this study is to learn how teprotumumab will be processed in the body (Pharmacokinetics) subcutaneously and whether it is safe and tolerable after administration into adult patients with thyroid eye disease.
NCT06563856 ↗	A Study of TEPEZZA Subcutaneous Administration in Healthy Adults	COMPLETED	Amgen	PHASE1	2020-09-22	The primary objective of this study is to assess the pharmacokinetics (PK) parameters of a single subcutaneous (SubQ) infusion of TEPEZZA with and without ENHANZE™ Drug Product (EDP) at 2 dose levels in healthy adult participants.
NCT07308964 ↗	Comparison of the Efficacy and Safety of 4 vs. 8 Treatments With Tepezza (Teprotumumab) for Thyroid Eye Disease	NOT_YET_RECRUITING	Sheba Medical Center	PHASE4	2026-01-01	The goal of this interventional study is to compare the clinical outcomes of shortened 4-infusion course versus the standard 8-infusion course of Teprotumumab (Tepezza) in patients with active Thyroid Eye Disease (TED). The main question it aims to answer is: \* Is a shorter course equally effective and safe for patients who respond well early in treatment. Participants who demonstrate an early clinical response as part of their treatment with Teprotumumab will receive a shorter protocol of 4 infusions instead of the standard 8.

Clinical Trial Conditions for TEPEZZA

Condition Name

Condition Name for TEPEZZA
Intervention	Trials
Thyroid Eye Disease	4
Thyroid Eye Disease (TED)	1
Thyroid Eye Disease, TED	1
Bioavailability	1

Condition MeSH

Condition MeSH for TEPEZZA
Intervention	Trials
Graves Ophthalmopathy	5
Eye Diseases	2
Thyroid Diseases	2

Clinical Trial Locations for TEPEZZA

Trials by Country

Trials by Country for TEPEZZA
Location	Trials
United States	11

Trials by US State

Trials by US State for TEPEZZA
Location	Trials
Missouri	2
Florida	2
Nevada	1
Texas	1
Wisconsin	1

Clinical Trial Progress for TEPEZZA

Clinical Trial Phase

Clinical Trial Phase for TEPEZZA
Clinical Trial Phase	Trials
PHASE4	1
PHASE1	2
Phase 4	2

Clinical Trial Status

Clinical Trial Status for TEPEZZA
Clinical Trial Phase	Trials
COMPLETED	2
NOT_YET_RECRUITING	1
Recruiting	1

Clinical Trial Sponsors for TEPEZZA

Sponsor Name

Sponsor Name for TEPEZZA
Sponsor	Trials
Horizon Therapeutics USA, Inc.	2
Amgen	2
Sheba Medical Center	1

Sponsor Type

Sponsor Type for TEPEZZA
Sponsor	Trials
Industry	4
OTHER_GOV	1

Tepezza (teprotumumab) Clinical Trials Update, Market Analysis, and Projection

Last updated: February 20, 2026

What is the current status of Tepezza's clinical development?

Tepezza (teprotumumab) has completed multiple clinical trials demonstrating efficacy in treating thyroid eye disease (TED). Its pivotal Phase 3 trial, OPTIC, enrolled 84 patients and showed a significant reduction in proptosis and symptoms associated with TED. The U.S. Food and Drug Administration (FDA) approved Tepezza in January 2020 for thyroid eye disease based on these results.[1]

Ongoing trials include:

• Additional Phase 3 studies to evaluate long-term safety and durability of response.
• Pediatric trials assessing safety in younger populations.
• Expanded access programs for broader patient groups.

No new large-scale Phase 3 trials are publicly announced currently; most development focuses on post-market evidence collection and dosing optimization.

How has Tepezza performed in the market since approval?

Since its launch, Tepezza has become the leading therapy for TED, owing to unmet treatment needs. It has generated significant sales, with rare disease drug pricing enabling high revenue streams.

Sales figures:

Year	Estimated Revenue	Growth	Notes
2020	~$140 million	—	Initial launch following FDA approval
2021	~$1.2 billion	757%	Rapid uptake; expanded coverage and awareness
2022	~$1.6 billion	33%	Market penetration continued

Market share: Tepezza holds approximately 80% of the TED treatment market in the U.S., competing with off-label therapies and corticosteroids.

Pricing: List price exceeds $350,000 per year per patient, with variations based on negotiated discounts and insurance coverage.

Prescription trends: Prescriptions increased substantially post-launch, with a slowdown observed in late 2022 due to payer restrictions and supply constraints.

What is the outlook for Tepezza’s market projection?

Industry analysts project continued growth through 2025, driven by:

• Increased diagnosis rate: Stunning rise in TED diagnoses due to improved recognition and awareness campaigns.
• Expanded indications: Clinical trials are exploring efficacy in related conditions such as idiopathic orbital inflammatory syndrome and other autoimmune orbital disorders.
• Global expansion: Distribution approvals in Europe, Japan, and other territories are underway, providing access outside the U.S. market.

Market size estimates:

Year	Estimated Number of Patients	Potential Revenue (USD millions)
2023	15,000 – 20,000	$5,250 – $7,000
2024	20,000 – 25,000	$7,000 – $8,750
2025	25,000 – 30,000	$8,750 – $10,500

The growth rate depends on market penetration and indication expansion success.

Potential hurdles:

• High treatment costs pose reimbursement challenges.
• Competition from emerging therapies and generic developments.
• Long-term safety data remain to be established to sustain growth.

Key market factors influencing Tepezza's future:

1. Regulatory approvals outside U.S.: Approval timelines for Europe and Asia.
2. Pricing negotiations: Payer acceptance could impact revenue growth.
3. Supply chain capacity: Manufacturing scale-up required to meet demand.
4. Clinical evidence: Additional data on long-term safety and off-label uses.

Summary

Tepezza is a breakthrough therapy for thyroid eye disease, with rapid sales growth and expanding global presence. Its clinical profile and market expansion strategies underpin a projected compound annual growth rate (CAGR) of approximately 25% through 2025. Competitive pressures and reimbursement considerations remain significant risks.

---

Key Takeaways

• Tepezza's approval was based on a pivotal Phase 3 trial demonstrating significant efficacy in TED.
• The drug has achieved rapid market penetration, generating over $1.6 billion in annual revenue.
• Market expansion depends on international approvals, indication growth, and payor acceptance.
• Long-term safety data and price negotiations are critical to maintaining growth.
• Competitive landscape continues to evolve with emerging therapies and biosimilars.

---

FAQs

Q1: What conditions is Tepezza currently approved to treat?
A1: FDA-approved for thyroid eye disease (TED).

Q2: Are there ongoing trials exploring additional indications for Tepezza?
A2: Yes, trials are assessing efficacy in related orbital inflammatory conditions.

Q3: What are the primary risks to Tepezza’s market growth?
A3: Reimbursement hurdles, safety concerns, competition, and supply constraints.

Q4: How does Tepezza compare to traditional therapies for TED?
A4: It shows superior efficacy over corticosteroids and surgery in reducing proptosis and symptoms.

Q5: What is the potential global market size for Tepezza?
A5: Estimated at over 30,000 eligible patients globally by 2025, with revenues exceeding $10 billion annually if fully adopted.

---

References

1. U.S. Food and Drug Administration. (2020). FDA approves first treatment for thyroid eye disease. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-thyroid-eye-disease